1. Introduction {#sec1-healthcare-05-00086}
===============

In the United States (U.S.), approximately 26,900 cases of high-risk human papilloma virus (HPV)-attributed genital and oropharyngeal cancers occur annually \[[@B1-healthcare-05-00086]\]. Overall, there are 38,793 HPV-attributed cancers annually in the U.S., an incidence of 11.7 per 100,000 persons \[[@B2-healthcare-05-00086]\]. High-risk oncogenic HPV types 16, 18, 31, 33, 45, 52, and 58 are associated with 92% of HPV-attributable cancers \[[@B2-healthcare-05-00086]\]. Low-risk non-oncogenic HPV types 6 and 11 are responsible for 96--100% of external genital warts (EGW) that have an incidence of 205 persons per 100,000 persons, affecting up to one million Americans annually \[[@B3-healthcare-05-00086],[@B4-healthcare-05-00086],[@B5-healthcare-05-00086]\]. Low-risk, non-oncogenic HPV Types 6 and 11 also cause 0.43 to 4.3 cases of recurrent respiratory papillomatosis (RRP) per 100,000 children, and 1.8 cases of RRP per 100,000 adults \[[@B6-healthcare-05-00086],[@B7-healthcare-05-00086]\]. The prevalence of high-risk oncogenic HPV ranges from 16.6 to 65.3%, in American men ages 18 to 44 and American women ages 18 to 35, while low-risk non-oncogenic HPV prevalence ranges from 13.5 to 25.3% \[[@B3-healthcare-05-00086],[@B8-healthcare-05-00086]\]. All told, this amounts to 75% of Americans experiencing an HPV infection once in their life \[[@B9-healthcare-05-00086]\].

The U.S. spent at least \$700 million in 2009 on HPV-attributable diseases \[[@B10-healthcare-05-00086]\]. Global approval of HPV vaccines began in 2006. The quadrivalent and nonavalent HPV vaccines (4vHPV and 9vHPV) prevent HPV-attributed cervical cancer, EGW, and RRP \[[@B4-healthcare-05-00086],[@B7-healthcare-05-00086],[@B11-healthcare-05-00086]\]. 4vHPV provides immunity from HPV-6, -11, -16, and -18. 9vHPV also provides immunity from HPV-31, -33, -45, -52, and -58 \[[@B2-healthcare-05-00086]\].

In 2009, a school-based 65% 3-dose HPV vaccination rate for Australian females ages 12--26, reduced the incidence of female and male EGW by 16.7 and 20 percentage-points respectively \[[@B12-healthcare-05-00086]\]. Subsequently, Australia achieved a 79% vaccination rate \[[@B13-healthcare-05-00086],[@B14-healthcare-05-00086],[@B15-healthcare-05-00086]\]. Higher school-based 3-dose HPV vaccination rates are 85% in Brazil and 81% in Britain \[[@B14-healthcare-05-00086],[@B15-healthcare-05-00086]\]. In pre-HPV vaccination approval China, parental HPV vaccine acceptance was 36.2% \[[@B16-healthcare-05-00086]\]. France, like the U.S. lacks a national HPV vaccination program \[[@B13-healthcare-05-00086]\]. France had a 38% adolescent female HPV vaccination series completion rate in 2013 \[[@B13-healthcare-05-00086]\]. This is closer to the U.S.' primarily clinic-based 32% female 3-dose HPV vaccination rate, than that obtained by school-based vaccination programs worldwide \[[@B17-healthcare-05-00086]\]. Adolescent girls (13--17 years old) in the U.S. fared slightly better with a 40% vaccination rate in 2014 \[[@B9-healthcare-05-00086],[@B18-healthcare-05-00086]\]. Conversely, adolescent boys in the U.S. fared worse with a 22% vaccination rate \[[@B9-healthcare-05-00086],[@B18-healthcare-05-00086],[@B19-healthcare-05-00086]\]. Underlying the importance of high HPV series vaccination rates, states with 3-dose adolescent female HPV vaccination rates of less than 33.9% in 2013 are associated with moderate and high age-adjusted cervical cancer incidence, 6.76 to 9.75 per 100,000 \[[@B20-healthcare-05-00086]\].

Parental HPV-vaccination acceptance may be most strongly associated with attitude, habit, intention, and subjective norms, providing direction for vaccination education \[[@B21-healthcare-05-00086]\]. Media campaigns targeted to the Latino population led to a 15% increase in immunizations in California \[[@B22-healthcare-05-00086]\]. A Vietnamese language media-led information and education campaign in Texas achieved a 21.5 percentage-point increased awareness of Hepatitis B, a 31.9 percentage-point increase in awareness of free childhood vaccinations, and a 14 percentage-point increase in awareness that Hepatitis B is sexually transmitted \[[@B23-healthcare-05-00086]\]. The Guildford County North Carolina HPV Campaign presentation to healthcare staff, parents, and school staff increased parents' post-intervention knowledge of HPV-attributable disease by 31% \[[@B24-healthcare-05-00086]\]. After the presentation, 97% of Guilford County, North Carolina parents were supportive of a school-based HPV vaccination clinic \[[@B24-healthcare-05-00086]\]. Given that electronic-based HPV vaccine education can be 23% more costly than print-based HPV vaccine education, educational method relative effectiveness is important \[[@B25-healthcare-05-00086]\].

Public education can address adverse events of vaccines in general, the HPV vaccine specifically, and refute the assumption that HPV vaccination results in rebound increased sexual activity \[[@B26-healthcare-05-00086]\]. Public education can also address the epidemiology of HPV-attributed infections, susceptibility to HPV-attributed infections, and societal burden thereof, leading to HPV vaccination recommendation. As 19% of parents are unsupportive of HPV vaccination, unless all other eligible children receive HPV vaccination, the U.S. cannot achieve an 80% or greater HPV vaccination completion rate for grade-school age children, necessary for herd immunity \[[@B9-healthcare-05-00086],[@B27-healthcare-05-00086]\]. Attainment of HPV herd immunity protecting the un-vaccinated would reduce HPV-attributed disease in the U.S. If counseling interventions can steer parents who initially would not accept HPV vaccination to accept HPV vaccination, an 80% or greater HPV vaccination completion rate is achievable. The objective of this quantitative comparative study was to evaluate whether multimodal counseling interventions increased HPV vaccination series non-completers' knowledge of HPV-attributable disease and acceptance of HPV-attributable disease prophylaxis (vaccination), over a control 14-sentence counseling intervention.

2. Materials and Methods {#sec2-healthcare-05-00086}
========================

We performed a single-blind, quantitative, four group, probability sampling, simple randomized, pre-test/post-test online survey ([Figure 1](#healthcare-05-00086-f001){ref-type="fig"}) with a minimum of 260 participants per study group, comprised half of young adults and half of parents, about 60:40 female to male ratio, totaling 1109 participants overall ([Figure 1](#healthcare-05-00086-f001){ref-type="fig"} and [Figure 2](#healthcare-05-00086-f002){ref-type="fig"}, and [Table 1](#healthcare-05-00086-t001){ref-type="table"}). Response tracking for partial and complete respondents was used. Invitation tracking for unopened or bounced (undeliverable) online invitation accounting was not used. All participants completed an online 25-item demographic questionnaire including initial screening items ([Questionnaire S1--S4](#app1-healthcare-05-00086){ref-type="app"}). All four groups responded to the pre-test 49-item HPV Knowledge and Acceptance survey, completed their assigned independent variable, and completed the post-test 49-item HPV Knowledge and Acceptance survey. All questionnaires had a young adult version and a parent version ([Questionnaires S2 and S3](#app1-healthcare-05-00086){ref-type="app"}). Quantitative analysis of survey items 1--25, from pre- and post-tests of all four groups, formed this study. Prior to data collection, this study received an exempt status from the A. T. Still University Institutional Review Board ([Permission S1](#app1-healthcare-05-00086){ref-type="app"}).

The first and control level counseling intervention received by all study groups was a 14-sentence informational brief, provided as [Intervention S1](#app1-healthcare-05-00086){ref-type="app"} \[[@B28-healthcare-05-00086]\]. The second level counseling intervention comprised the 14-sentence informational brief and a 4.34-min audiovisual *Why vaccinate against HPV* \[[@B29-healthcare-05-00086]\]. The third level counseling intervention was the 14-sentence informational brief and a public health education handout (PHEH) based on the *Public Health Fact Sheet*: *Patient information about HPV and the HPV vaccine* ([Intervention S2](#app1-healthcare-05-00086){ref-type="app"}) \[[@B30-healthcare-05-00086]\]. The fourth level counseling intervention comprised the 14-sentence informational brief, the audiovisual, and the PHEH. Consents were obtained for all independent variable use ([Permissions S2--S4](#app1-healthcare-05-00086){ref-type="app"}). The HPV Knowledge and HPV Vaccination Acceptance survey, comprised of the Parental HPV Survey, validated for use with 5-point Likert scale coded responses with Cronbach's alphas \>0.95, a validated 3-item HPV acceptance questionnaire, both available without express consent for educational purposes, and a consented adaptation of focused interview questions \[[@B26-healthcare-05-00086],[@B27-healthcare-05-00086],[@B28-healthcare-05-00086]\].

In February 2015, SurveyMonkey Audience invited Americans 19 years and older to participate via age-based probability sampling with simple randomization to groups. SurveyMonkey Audience protocol determined the participation incentive. Eligible participants were age 19 or older, able to read and accept an online Survey Participation Consent in English, able to complete the online survey in English, and had not completed the HPV vaccination series. Young adults, age 19--26 years could participate offering opinions for themselves without regard to any child(ren) they may have. Young adults could not also participate as parents. Interested persons progressed to the inclusion/exclusion criteria items. Consent was implied once a potential participant proceeded to the survey instrument screen. Of 2312 initial respondents, 1470 were eligible, and 1109 eligible participants (75.4%) completed the survey ([Figure 2](#healthcare-05-00086-f002){ref-type="fig"}).

The online survey host, SurveyMonkey Audience, directly invited potential participants from its database and maintained the anonymity of potential and actual study participants. Data lacking identifiers, IP, or email address tracking was collected via encrypted secure sockets layer/transport layer security technology (SSL/TLS) connections in February 2015. The survey lacked name, address, or contact information fields. Participant data storage followed the standard SurveyMonkey Audience anonymous data storage protocol: user authentication and user passwords for data access, and continued data encryption while stored in an audited secure data center.

Statistical analysis was performed using IBM SPSS Statistics (IBM Corp., Armonk, NY, USA), package Version 22. Normality testing with Kolmogorov-Smirnov and Shapiro-Wilk tests at *p* \< 0.05 ascertained a lack of normally distributed demographics, knowledge, and acceptance items responses. Therefore, count and frequency descriptive statistics were used for the sample description. Chi-square was used to ascertain randomization validity. Spearman's rank correlation coefficient (ρ) was used for comparisons between interval and ordinal variables \[[@B31-healthcare-05-00086]\].

Quantitative HPV knowledge and HPV vaccination acceptance items were analyzed for the 1109 respondents who completed the survey through the end of the quantitative post-test. Responses were extracted and analyzed as two groups, as well as individually. Given the lack of normality and the use of four study groups, two-tailed non-parametric tests at alpha level α ≤ 0.05 were employed: Kruskal-Wallis analysis of variance by ranks (*χ*^2^), Mann-Whitney *U* test with Bonferroni correction, and Wilcoxon signed-ranks test (*T*).

3. Results {#sec3-healthcare-05-00086}
==========

Childless young adults who had not completed a HPV vaccination series and parents whose child(ren) had not completed a HPV vaccination series were the study population. Prior completion of the HPV vaccination series was the primary cause of study ineligibility ([Figure 2](#healthcare-05-00086-f002){ref-type="fig"}). The study had a 75.4% completion rate. Pre-test attrition was the most common form of attrition loss (67.3%). [Table 1](#healthcare-05-00086-t001){ref-type="table"} and [Figures S1--S4](#app1-healthcare-05-00086){ref-type="app"} describe the 1109 respondents who completed the survey through the end of the quantitative post-test. The resulting sample had a positively skewed age distribution, comprised of 545 childless young adults ages 19--26, and 564 parents age 27 years or older ([Figure 2](#healthcare-05-00086-f002){ref-type="fig"}, [Figures S1--S4](#app1-healthcare-05-00086){ref-type="app"} and [Table 1](#healthcare-05-00086-t001){ref-type="table"}). Childless young adults were more likely to have never married than were parents (64.8% and 9.4% respectively), and more likely to have had some college education than parents (35% and 26.2% respectively). However, parents were more likely to have graduated from college or graduate school than were childless young adults (41.1% and 16.5% versus 26.4% and 5.5%, respectively). Parents were more likely to accept offers of HPV vaccination for a child than were childless young adults for themselves (68.2% versus 52.9%, respectively).

Chi-square analysis ascertained valid random assignment of participants to intervention groups based on 15 nominal independent variables excluding insurance status, marital status, race and ethnicity, and religion ([Table 1](#healthcare-05-00086-t001){ref-type="table"}). Human Papilloma Virus vaccination acceptance and insurance type were imbalanced (*p* = 0.029 and *p* = 0.038 respectively) ([Table 1](#healthcare-05-00086-t001){ref-type="table"}). Due to category assignments of less than five per intervention group, 2-sided Fisher's exact tests were calculated for marital status and religion, resulting in *p* \< 0.001 in each case. For race and ethnicity, one-quarter of Pearson Chi-Square cells had expected cell frequencies of fewer than 5 participants. Fisher's exact test could not be run. The Yates Continuity Correction and the Pearson Chi-Square were equal at 0.734.

To determine differences in pre- to post-test knowledge of HPV-attributable diseases and prophylaxis between multimodal counseling interventions for HPV vaccination among series non-completers, the change in number of participants making *agree* or *strongly agree* responses to the 11-item knowledge variable subscale was analyzed ([Table 2](#healthcare-05-00086-t002){ref-type="table"}, [Table 3](#healthcare-05-00086-t003){ref-type="table"} and [Table 4](#healthcare-05-00086-t004){ref-type="table"}). Kruskal-Wallis analysis of variance by ranks (*χ*^2^) of the 18.0% to 19.9% increases in the number of participants with knowledge subscale *agree* or *strongly agree* responses in Groups 2 and 3 indicated statistical significance, *p* = 0.038 ([Table 3](#healthcare-05-00086-t003){ref-type="table"}). Follow-up Mann-Whitney *U* testing with Bonferroni correction, showed Group 2 had statistically significant increases in the number of participants with more than half knowledge subscale *agree* or *strongly agree* responses (*p* = 0.04) as shown in [Table 5](#healthcare-05-00086-t005){ref-type="table"}. Groups 2 and 3 achieved statistically significant knowledge improvement of HPV etiologic role in occurrence of EGW, *p* \< 0.001. Group 3 achieved statistically significant knowledge improvement pertaining to the purposes of HPV vaccination, *p* = 0.02. Wilcoxon signed-ranks test identified six knowledge items with statistically significant changes in responses using the range of the 5-point Likert scale from pre-test to post-test, with small or medium effect sizes as shown in [Table 6](#healthcare-05-00086-t006){ref-type="table"} \[[@B32-healthcare-05-00086]\].

To determine the effect, if any, of covariates on HPV knowledge and HPV vaccination acceptance, Spearman's rank correlation coefficient (ρ) was calculated. Unadjusted ρ, demonstrated that parents' age in years, and US generation status were significantly correlated with increased HPV knowledge (*p* = 0.027 and *p* = 0.032 respectively) and HPV vaccination acceptance (*p* = 0.005 and *p* = 0.032 respectively), resulting in more than half *agree* and *strongly agree* responses ([Table 7](#healthcare-05-00086-t007){ref-type="table"}). The number of doses of HPV vaccine received affected increased HPV vaccination acceptance (*p* = 0.011), while the number of male children a parent had was significantly correlated (*p* = 0.028) with increased HPV knowledge resulting in more than half *agree* and *strongly agree* responses.

To ascertain differences in reported HPV vaccination acceptance rates of HPV vaccination series non-completers across multimodal counseling interventions, the pre-test to post-test change in the number of participants responding *agree* or *strongly agree* to the 14-item acceptance variable subscale items was analyzed. Kruskal-Wallis analysis of variance by ranks (*χ*^2^) of the 12.2% to 12.6% increases in the number of participants with acceptance subscale *agree* or *strongly agree* responses in Groups 1 and 3 respectively ([Table 3](#healthcare-05-00086-t003){ref-type="table"}) did not demonstrate statistical significance. Wilcoxon signed-ranks test indicated eight HPV vaccination acceptance items with statistically significant changes in responses using the 5-point Likert scale from pre-test to post-test, *p* \< 0.001 to *p* = 0.023; however, the effect sizes were small or medium as shown in [Table 6](#healthcare-05-00086-t006){ref-type="table"} \[[@B32-healthcare-05-00086]\]. For Group 1, the audiovisual intervention, there were six such items: "A3. Research improves vaccines", *p* = 0.006, "A5. HPV vaccination would prevent problems for myself/my child(ren)", *p* = 0.002, "A7. HPV vaccination before teenage is a good idea", *p* = 0.002, "A9. If the HPV vaccine were available, I/my child(ren) would be vaccinated against HPV", *p* = 0.002, "A12. Despite cost I will vaccinate myself/my child(ren)", *p* \< 0.001, and "A13. If my doctor recommends I will vaccinate myself/my child(ren)", *p* = 0.042. For Group 3, the combined audiovisual and PHEH intervention, there were seven such items: "A3. Research improves vaccines", *p* = 0.001, "A5. HPV vaccination would prevent problems for myself/my child(ren)", *p* \< 0.001, "A7. HPV vaccination before teenage is a good idea", *p* = 0.001, "A8. Teenagers should be able to get HPV vaccination without parental consent", *p* = 0.023, "A11. Will only vaccinate myself/my child(ren) against HPV if required", *p* = 0.002, "A12. Despite cost I will vaccinate myself/my child(ren)", *p* \< 0.001, and "A13. If my doctor recommends I will vaccinate myself/my child(ren)", *p* = 0.05.

4. Discussion {#sec4-healthcare-05-00086}
=============

The objective of this quantitative comparative online survey-based study was to evaluate whether multimodal counseling interventions increase HPV vaccination series non-completers' knowledge of HPV-attributable disease and acceptance of HPV-attributable disease prophylaxis (vaccination), over a control 14-sentence counseling intervention. Given individuality, it is plausible that different counseling interventions will be necessary to reach different people. Different counseling interventions may have different efficacy. Counseling interventions can increase disease process and vaccination knowledge and acceptance by 9.2 to 15 percentage-points \[[@B23-healthcare-05-00086],[@B33-healthcare-05-00086],[@B34-healthcare-05-00086]\]. However, evidence-based practice and economical resource use require case-by-case counseling intervention outcomes evaluations. Therefore, this head-to-head study design evaluated three counseling interventions with a control standard of care counseling intervention. An effective counseling intervention would simultaneously increase HPV knowledge, and HPV vaccination knowledge and acceptance. Effective counseling intervention use could help raise the U.S.' female HPV vaccination rate from 32% to an achievable, beneficial, potentially herd immunity sustaining 80%.

This study found that compared to the control group, all experimental groups showed a greater increase in HPV-attributable disease and HPV vaccination knowledge, *p* = 0.038. The PHEH intervention, and the combined audiovisual and PHEH intervention, raised knowledge of HPV-attributable EGW, *p* \< 0.001 ([Table 5](#healthcare-05-00086-t005){ref-type="table"}). The combined audiovisual and PHEH intervention raised knowledge of HPV vaccination purpose, *p* = 0.02 ([Table 5](#healthcare-05-00086-t005){ref-type="table"}). In a primarily Caucasian or Hispanic public health and private pediatric clinic population preintervention parental knowledge that HPV is causative of EGW may range from 16.43 to 36.25% respectively \[[@B19-healthcare-05-00086]\].

In this study, preintervention knowledge that EGW is an HPV-attributable disease was 44.82%, and of HPV vaccination purpose 41.57% ([Table 4](#healthcare-05-00086-t004){ref-type="table"}). Thus, this study population's preintervention knowledge of HPV-attributable EGW ([Table 4](#healthcare-05-00086-t004){ref-type="table"}) is comparable to that of the aforementioned private pediatric clinic population \[[@B19-healthcare-05-00086]\]. However, in both instances, preintervention knowledge was noticeably less than that found among community outreach participants in north central Florida, 74.2%, when asked if HPV causes EGW and cervical cancer \[[@B35-healthcare-05-00086]\]. Similarly, 74.3% of medical students at a midwestern U.S. medical school were aware that HPV vaccination protects against EGW, and 91.1% were aware that HPV vaccination protects against cervical cancer, both of which represent higher background HPV knowledge than evident in this study's population \[[@B18-healthcare-05-00086]\].

The combined PHEH and audiovisual achieved increased HPV vaccination acceptance for seven items, *p* \< 0.001 to *p* = 0.023 ([Table 6](#healthcare-05-00086-t006){ref-type="table"}). The audiovisual intervention achieved increased HPV vaccination acceptance for six items, *p* \< 0.001 to *p* = 0.006 ([Table 6](#healthcare-05-00086-t006){ref-type="table"}). Parents were more likely to accept offers of HPV vaccination for a child than were childless young adults for themselves (68.2% and 52.9%). Particularly, parents of more sons than daughters were more likely to accept HPV vaccination. While previous investigators excluded fathers and young male adults from their studies, or had low inclusion of fathers, such as 9% of the sample, in this study fathers and young male adults were 18% and 21% respectively of the sample \[[@B24-healthcare-05-00086],[@B28-healthcare-05-00086],[@B36-healthcare-05-00086],[@B37-healthcare-05-00086]\]. The inclusion of 39% male participants may have played into the finding that parents of sons retained the most information about HPV.

The finding that generational status remote from an immigration event is associated with increased knowledge and acceptance of HPV is contrary to Bair et al.'s finding that temporal proximity to an immigration event increased the likelihood to accept vaccination \[[@B38-healthcare-05-00086]\]. Yet, these findings are consistent with the literature on older adults and health promotion. Earlier studies found older adults were more likely to participate in health promoting behaviors than were younger adults \[[@B39-healthcare-05-00086],[@B40-healthcare-05-00086]\]. The association between increased likelihood to accept HPV vaccination and generational status remote from an immigration event is consistent with foreign-born persons living in the U.S. having lower HPV vaccination initiation rates \[[@B41-healthcare-05-00086]\].

The findings are both statistically and clinically significant. Clinically, the findings suggest that EGW prevention may motivate HPV vaccination acceptance, and that older parents are more accepting of HPV vaccination than are childless young adults. Parents of male children retained the most knowledge information about HPV vaccination. Given that less intervention is needed to move a person from contemplation to action, than from pre-contemplation to action, participating parents of male children may have been in a contemplative state about HPV, whereas young adults and parents of daughters could have been pre-contemplative \[[@B42-healthcare-05-00086]\]. Additionally, as proportionately more parents than childless young adults were initially accepting of HPV vaccination, adults overall may be more likely to be contemplative towards HPV vaccination than childless young adults. For different age groups, different knowledge and acceptance factors, equivalent to pros and cons of vaccination can facilitate a movement to action \[[@B42-healthcare-05-00086]\]. Contemplative male participants are consistent with Patel et al., who found 57.9% of males to be contemplative, but inconsistent with Perez et al., who found at least 77.9% of parents of sons to be pre-contemplative of male HPV vaccination \[[@B43-healthcare-05-00086],[@B44-healthcare-05-00086]\]. Nonetheless, knowledge and awareness increasing educational counseling interventions are targeted for precontemplation and contemplation stages of behavioral change, making parents and young male adults the best targets for the multimodal counseling interventions used in this study \[[@B45-healthcare-05-00086]\].

Targeted counseling for HPV vaccination acceptance has demonstrated ability to increase HPV vaccination acceptability \[[@B24-healthcare-05-00086],[@B26-healthcare-05-00086],[@B33-healthcare-05-00086],[@B35-healthcare-05-00086]\]. Gain-framed counseling can convince mothers of sons to consider HPV vaccination \[[@B46-healthcare-05-00086]\]. Previous investigators had found cervical cancer prevention was a greater motivator for HPV vaccination acceptance than prevention of a sexually transmitted infection \[[@B47-healthcare-05-00086]\]. Yet, this study found that EGW, a visible manifestation of an HPV-attributable STI was the most easily communicated HPV-attributed disease. Therefore, clinicians and health promotion initiatives could target households with male children and older parents for HPV vaccination promotion. Clinically, health care providers should realize young adults, households with more female than male children, and persons associated with a proximate American immigration event who have yet to accept HPV vaccination may be pre-contemplative regarding HPV vaccination. In that case, more effort will be needed to make significant gains in HPV and HPV vaccination knowledge and acceptance. Well-designed handouts can be as effective, or more effective than an audiovisual presentation to help to shift stage of change towards contemplation, potentially reducing counseling costs.

There were several limitations to this study. The composite 25-item demographics questionnaire combined with a repeated 49-item survey instrument could have been excessively long \[[@B23-healthcare-05-00086],[@B24-healthcare-05-00086],[@B36-healthcare-05-00086],[@B48-healthcare-05-00086]\]. Long surveys may incur diminishing returns with subject fatigue contributing to satisficing behavior and poorer quality responses \[[@B49-healthcare-05-00086]\]. Despite the survey's length potentially important questions such as sexual orientation and unmarried persons' intimate relationship status, which affects perceived HPV vaccination need were omitted \[[@B9-healthcare-05-00086],[@B50-healthcare-05-00086]\]. The power to detect differences or adequately describe the target population was reduced by the small sampling of non-Hispanic mixed race, non-Hispanic other, and Hispanic other groups, a smaller proportion of Medicaid participants in the audiovisual intervention Group 1, and of vaccination refusers in the Control group.

Moreover, this consumer-based online study population is different from random-dial telephone HPV surveys populations, and college-student or other populations completing online surveys. Selection or response bias occurring with choosing which email to respond to may be different from that occurring when choosing to answer a telephone call. As response, not invitation tracking was used, the rates of invitations per respondent and per included respondent are unknown. Different self-selected populations may have different underlying interest in and knowledge of the topic being surveyed \[[@B18-healthcare-05-00086],[@B35-healthcare-05-00086]\]. Contrary to the literature, neither morality nor religiosity affected HPV vaccination acceptance \[[@B26-healthcare-05-00086],[@B27-healthcare-05-00086],[@B51-healthcare-05-00086]\]. Of course, this finding should be interpreted cautiously due to the sparse representation of several religious categories. Unlike Curtis et al., neither health care provider recommendation, income, residence location, the setting in which vaccines are received, nor race significantly affected HPV vaccination acceptance \[[@B52-healthcare-05-00086]\]. Also, contrary to the literature, education did not affect HPV vaccine acceptability \[[@B41-healthcare-05-00086],[@B45-healthcare-05-00086],[@B52-healthcare-05-00086],[@B53-healthcare-05-00086]\]. This consumer-based online study is further limited by the lack of provider- or pharmacy-verified vaccination histories. Participant provided HPV-vaccination status could reflect recall and social desirability biases \[[@B45-healthcare-05-00086]\].

The audiovisual choice may have not been as well received as the PHEH, reflected in greater response to the latter than the former. A combination of survey length and audiovisual choice may account for the combined audiovisual and PHEH Group 3 not standing out from the PHEH Group 2 as the most effective intervention. Future studies could be conducted with a larger proportion of over 40-years old; non-Hispanic mixed race, non-Hispanic other, and Hispanic other racial or ethnic groups to improve external generalization. A separate study evaluating audiovisual presentations to determine the most effective audiovisual could improve HPV vaccination counseling. Given a potential 23% cost differential in using electronic instead of print counseling materials, increased comparative audiovisual effectiveness is essential for audiovisual counseling use \[[@B25-healthcare-05-00086]\].

5. Conclusions {#sec5-healthcare-05-00086}
==============

The objective of this quantitative comparative online study was to evaluate whether multimodal counseling interventions increase HPV vaccination series non-completers' knowledge of HPV-attributable disease and acceptance of HPV-attributable disease prophylaxis (vaccination), over a control 14-sentence counseling intervention. The selected consumer-based online survey population has different characteristics than a random-dialed telephone or college-based online survey population. The results showed that some disease and vaccination-specific information could be successfully communicated in the online format yielding changed perceptions. Foremost, that HPV causes EGW, and that HPV vaccination prevents HPV-attributable diseases and their sequelae were better conveyed by the combined audiovisual presentation and PHEH than the control 14-sentence counseling intervention alone.

Funding: This is an unfunded work. Presentation at Meetings: A poster of this work was presented at the American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting, Washington DC, on 15 May 2016. An oral presentation of this work was given at the 2nd International Congress on Contemporary Issues in Women Cancers and Gynecologic Oncology, London, England, on 29 August 2017. Source of the work: The quantitative portion of the corresponding author's applied research project for the Doctor of Health Science degree, submitted to A. T. Still University.

The following are available online at [www.mdpi.com/2227-9032/5/4/86/s1](www.mdpi.com/2227-9032/5/4/86/s1). Questionnaire S1: Demographic Questionnaire, Questionnaire S2: Young adult HPV Knowledge and Acceptance survey, Questionnaire S3: Parent HPV Knowledge and Acceptance survey, Intervention S1: 14-sentence informational brief, Intervention S2: Public health education handout, Permission S1: A. T. Still University Institutional Review Board, Permission S2: Consent to use the 14-sentence informational brief, Permission S3: Permission to use the audiovisual intervention, Permission S4: Permission to use the public health education handout, Figure S1: Participant demographics: Age by group, Figure S2: Participant demographics: Biologic sex by group, Figure S3: Participant demographics: Children's biologic sex by group, Figure S4: Participant demographics: Race/ethnicity by group.

###### 

Click here for additional data file.

O.N. and H.S. conceived and designed the study; O.N. contracted Survey Monkey to host the survey; O.N. cleaned and coded the data, retrieved and analyzed the literature; O.N., H.S., and C.B. analyzed and interpreted the data; O.N. wrote the paper; O.N., H.S., and C.B. critically revised the prepublication drafts for important intellectual content; O.N., H.S., and C.B. approved the final version for publication.

C.B. and H.S. declare no conflict of interest. O.N. owns less than \$5000 common stock outside of mutual funds in both GlaxoSmithKline and Merck.

![Study design flowchart. A single-blind, quantitative, four group, simple randomized, repeated measures, pre-test/post-test design with sample of young adults and parents from total survey respondents.](healthcare-05-00086-g001){#healthcare-05-00086-f001}

![Participant flowchart. Sample of young adults and parents from total survey respondents. There were at least 260 participants per study group, comprised half of young adults and half of parents, with an approximately 60:40 female to male ratio, and a final sample size of 1109 participants.](healthcare-05-00086-g002){#healthcare-05-00086-f002}
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###### 

Independent variables randomization validation to group assignment.

  Independent Variables                        Control   Exp. Gp. 1   Exp. Gp. 2   Exp. Gp. 3   *N*   Valid   Chi-       Fischer's                               
  -------------------------------------------- --------- ------------ ------------ ------------ ----- ------- ---------- ----------- ----- ------- ------------- ---------
  Age (years)                                                                                                                                      0.211         
   Young adults 19--26                         138       25.3         125          22.9         134   24.6    148        27.2        545   49.1                  
   Parents 27 and older                        139       24.6         160          28.4         127   22.5    138        24.5        564   50.9                  
  Biologic sex                                                                                                                                     0.369         
   Female                                      151       23.9         157          24.8         160   25.3    165        26.1        633   57.1                  
   Male                                        126       26.5         128          26.9         101   21.2    121        25.4        476   42.9                  
  Sex of child(ren)                                                                                                                                0.225         
   Female and male                             45        19.5         65           28.6         59    25.5    61         26.4        231   41.0                  
   Male                                        51        30.0         51           30.0         32    18.8    36         21.2        170   30.1                  
   Female                                      43        26.4         43           26.4         36    22.1    41         25.2        163   28.9                  
  Marital Status                                                                                                                                                 \<0.001
   Married                                     131       25.5         138          26.9         126   24.6    118        23.0        513   46.3                  
   Single, never married                       110       27.1         87           21.4         100   24.6    109        26.8        406   36.6                  
   Long-term relationship                      18        17.1         28           26.7         23    21.9    36         34.3        105   9.5                   
   Separated, divorced, widowed                12        18.5         26           40.0         10    15.4    17         26.2        65    5.8                   
   Common law marriage                         6         30.0         6            30.0         2     10.0    6          30.0        20    1.8                   
  Household size                                                                                                                                   0.976         
   One person                                  25        28.1         25           28.1         15    16.9    24         27.0        89    8.0                   
   Two persons                                 40        22.9         46           26.3         41    23.4    48         27.4        175   15.8                  
   Three persons                               82        24.7         85           25.6         76    22.9    89         26.8        332   29.9                  
   Four persons                                77        26.1         71           24.1         72    24.4    75         25.4        295   26.6                  
   Five persons                                30        23.8         31           24.6         33    26.2    32         25.4        126   11.4                  
   Six or more persons                         23        25.0         27           29.3         24    26.1    18         19.6        92    8.3                   
  Household children                                                                                                                                             0.001
   None                                        3         12.5         11           45.8         3     12.5    7          29.2        24    2.2                   
   One child                                   178       26.3         164          24.2         152   22.4    184        27.1        678   61.1                  
   Two children                                59        21.1         83           29.6         64    22.9    74         26.4        280   25.2                  
   Three children                              24        29.3         14           17.1         28    34.1    16         19.5        82    7.4                   
   Four children                               9         36.0         3            12.0         10    40.0    3          12.0        25    2.3                   
   Five or more children                       4         20.0         10           50.0         4     20.0    2          10.0        20    1.8                   
  Race and ethnicity                                                                                                                               0.734 *^a^*   cannot
   White, non-Hispanic                         173       20.0         200          27.5         174   23.9    180        24.8        727   65.6                  compute
   Hispanic, White                             34        27.9         30           24.6         30    24.6    28         23.0        122   11.0                  
   African-American, non-Hispanic              28        30.0         24           22.2         20    18.5    36         33.3        108   9.7                   
   Asian, non-Hispanic                         19        30.0         19           25.0         15    19.7    23         30.3        76    6.9                   
   Hispanic, non-White                         10        29.4         7            20.6         7     20.6    10         29.4        34    3.1                   
   Mixed race, non-Hispanic                    7         28.0         3            12.0         9     36.0    6          24.0        25    2.3                   
   Other, non-Hispanic                         5         38.5         1            7.7          5     38.5    2          15.4        13    1.2                   
   Hispanic, Other                             1         25.0         1            25.0         1     25.0    1          25.0        4     0.4                   
  Religion                                                                                                                                                       \<0.001
   Other Christian                             58        22.6         62           24.1         60    23.3    77         30.0        257   23.2                  
   None                                        68        28.0         65           26.7         52    21.4    58         23.9        243   21.9                  
   Catholicism                                 56        28.3         50           25.3         52    26.3    40         20.2        198   17.9                  
   Baptist                                     33        21.4         42           27.3         33    21.4    46         29.9        154   13.9                  
   Protestantism                               24        24.7         25           25.8         27    27.8    21         21.6        97    8.7                   
   Other                                       21        22.3         21           22.3         23    24.5    29         30.9        94    8.5                   
   Mormonism                                   6         27.3         7            31.8         6     27.3    3          13.6        22    2.0                   
   Jewish                                      6         33.3         4            22.2         3     16.7    5          27.8        18    1.6                   
   Buddhism                                    3         21.4         5            35.7         2     14.3    4          28.6        14    1.3                   
   Islam                                       2         16.7         4            33.3         3     25.0    3          25.0        12    1.1                   
  Born-again or evangelical Christian                                                                                                              0.282         
   Yes                                         66        22.8         73           25.2         80    27.6    71         24.5        290   26.1                  
   No                                          211       25.8         212          25.9         181   22.1    215        26.3        819   73.9                  
  Frequency of religious services                                                                                                                  0.835         
   Rarely or never                             121       25.3         127          26.6         105   22.0    125        26.2        478   43.1                  
   A few times annually                        63        30.1         49           23.4         47    22.5    50         23.9        209   18.8                  
   1--3 times a month                          31        20.8         39           26.2         38    25.5    41         27.5        149   13.4                  
   Once weekly                                 44        22.3         51           25.9         49    24.9    53         26.9        197   17.8                  
   More than once weekly                       18        23.7         19           25.0         22    28.9    17         22.4        76    6.9                   
  Political leaning                                                                                                                                0.241         
   Very conservative                           42        25.9         51           31.5         35    21.6    34         21.0        162   14.6                  
   Somewhat conservative                       51        24.8         55           26.7         43    20.9    57         27.7        206   18.6                  
   Middle of the road                          93        21.3         111          25.4         112   25.6    121        27.7        437   39.4                  
   Somewhat liberal                            61        30.5         40           20.0         49    24.5    50         25.0        200   18.0                  
   Very liberal                                30        28.8         28           26.9         22    21.2    24         23.1        104   9.4                   
  Education level                                                                                                                                  0.448         
   Less than high school                       2         40.0         1            20.0         1     20.0    1          20.0        5     0.5                   
   Some high school                            7         20.6         9            26.5         9     26.5    9          26.5        34    3.1                   
   9th grade                                   2         15.4         4            30.8         3     23.1    4          30.8        13    1.2                   
   10th grade                                  2         22.2         3            33.3         2     22.2    2          22.2        9     0.8                   
   11th grade                                  3         25.0         2            16.7         4     33.3    3          25.0        12    1.1                   
   Completed high school/GED                   59        25.4         60           25.9         61    26.3    52         22.4        232   20.9                  
   Some college                                78        23.0         89           26.3         73    21.5    99         29.2        339   30.6                  
   College graduate                            95        25.3         88           23.4         100   26.6    93         24.7        376   33.9                  
   Graduate school                             36        29.3         38           30.9         17    13.8    32         26.0        123   11.1                  
  Household income                                                                                                                                 0.275         
   Less than \$20,000                          50        26.2         46           24.1         49    25.7    46         24.1        191   17.2                  
   \$20,000--\$39,999                          52        26.1         43           21.6         52    26.1    52         26.1        199   17.9                  
   \$40,000--\$49,999                          38        25.2         41           27.2         32    21.2    40         26.5        151   13.6                  
   \$50,000--\$59,999                          49        29.0         36           21.3         42    24.9    42         24.9        169   15.2                  
   \$60,000--\$100,000                         48        20.3         76           32.2         49    20.8    63         26.7        236   21.3                  
   More than \$100,000                         28        28.9         30           30.9         16    16.5    23         23.7        97    8.7                   
   Declined to answer                          12        18.2         13           19.7         21    31.8    20         30.3        66    6.0                   
  Employment status                                                                                           0.441                                0.441         
   Full time employee                          111       24.4         115          25.3         113   24.8               25.5        455   41.0                  
   Homemaker                                   54        25.0         60           27.8         56    25.9               21.3        216   19.5                  
   Part time employee                          52        28.1         38           20.5         43    23.2               28.1        185   16.7                  
   Full time student, not working              26        19.8         38           29.0         26    19.8               31.3        131   11.8                  
   Unemployed                                  34        27.9         34           27.9         23    18.9               25.4        122   11.0                  
  Location of home                                                                                            0.923                                0.923         
   Urban                                       85        24.5         90           26.0         81    23.4               26.0        346   31.2                  
   Suburban                                    126       24.3         134          25.8         119   22.9               27.0        519   46.8                  
   Rural                                       66        27.0         61           25.0         61    25.0               23.0        244   22.0                  
  Type of health insurance                                                                                    0.038 \*                             0.038 \*      
   Private                                     146       22.6         180          27.8         143   22.1               27.5        647   58.3                  
   Medicaid                                    80        29.4         53           19.5         74    27.2               23.9        272   24.5                  
   Other                                       51        26.8         52           27.4         44    23.2               22.6        190   17.1                  
  Vaccination setting                                                                                         0.863                                0.863         
   Healthcare provider's office                195       25.0         204          26.2         183   23.5               25.3        779   70.2                  
   Hospital                                    42        25.8         38           23.3         43    26.4               24.5        163   14.7                  
   Community clinic                            23        21.1         31           28.4         22    20.2               30.3        109   9.8                   
   County clinic                               17        29.3         12           20.7         13    22.4               27.6        58    5.2                   
  Frequency of healthcare visits                                                                              0.579                                0.579         
   Annual checkup                              130       23.0         15           27.0         134   23.8               26.2        564   50.9                  
   Only when sick                              119       26.1         115          25.2         104   22.8               25.9        456   41.1                  
   Other                                       28        31.5         18           20.2         23    25.8               22.5        89    8.0                   
  Regular healthcare provider                                                                                 0.154                                0.154         
   Yes                                         210       23.6         232          26.1         209   23.5               26.8        889   80.2                  
   No                                          67        30.5         53           24.1         52    23.6               21.8        220   19.8                  
  US Generation *^b^* (*n* = 1108)                                                                            0.321                                0.321         
   First generation                            38        30.9         30           24.4         23    18.7               26.0        123   12.1                  
   Second generation                           38        28.1         26           19.3         31    23.0               29.6        135   13.3                  
   Third generation                            180       23.7         204          26.8         178   23.4               26.1        760   74.7                  
  Know someone with a STD                                                                                     0.625                                0.625         
   Yes                                         101       24.8         97           23.8         103   25.3               26.0        407   36.7                  
   No                                          176       25.1         188          26.8         158   22.5               25.6        702   63.3                  
  Personally had a STD                                                                                        0.555                                0.555         
   Yes                                         27        23.3         25           21.6         32    27.6               27.6        116   10.5                  
   No                                          250       25.2         260          26.2         229   23.1               25.6        993   89.5                  
  Ever heard of HPV                                                                                           0.850                                0.850         
   Yes                                         221       25.0         230          26.0         210   23.8               25.2        884   79.7                  
   No                                          56        24.9         55           24.4         51    22.7               28          225   20.3                  
  Ever heard of HPV vaccine                                                                                   0.684                                0.684         
   Yes                                         214       25.3         215          25.4         204   24.1               25.1        845   76.2                  
   No                                          63        23.9         70           26.5         57    21.6               28.0        264   23.8                  
  Offered HPV vaccine for child(ren) or self                                                                  0.566                                0.566         
   Yes                                         82        22.7         92           25.5         92    25.5               26.3        361   32.6                  
   No                                          195       26.1         193          25.8         169   22.6               25.5        748   67.4                  
  Accepted HPV vaccine *^c^* (*n* = 218)                                                                                                           0.029 \*      
   Yes                                         61        27.1         54           24.0         47    20.9    63         28.0        218   60.4                  
   No                                          26        17.3         38           25.3         49    32.7    37         24.7        143   39.6                  
  HPV vaccine doses *^d^* (*n* = 219)                                                                                                219           0.054         
   None                                        3         25.0         1            8.3          6     50.0    2          16.7        12    5.5                   
   One dose                                    39        26.9         40           27.6         22    15.2    44         30.3        145   66.21                 
   Two doses                                   16        25.8         54           21.0         18    29.0    15         24.2        62    28.3                  

*^a^* 8 cells (25%) have expected count less than 5, Yates continuity correction. 734 = Pearson Chi-Square. *^b^* (*n* = 1108) as there were 91 foreign born participants. *^c^* (*n* = 218) is the number of included participants who were offered and accepted HPV vaccine, but who did not complete the 3-dose HPV vaccination series. *^d^* (*n* = 219) includes one subject who was not offered, but received HPV vaccine. \* denotes statistical significance the alpha = *p* = 0.05 level. Due to rounding percentages may not add up to 100. Exp. Gp. = Experimental Group; GED = General education development certificate; HPV = Human papilloma virus; STD = sexually transmitted disease; US = United States of America.

healthcare-05-00086-t002_Table 2

###### 

Intervention group scale summary: More than half post-test responses showing HPV Knowledge and HPV vaccination acceptance.

  Scale                 Control *^a^* (*n* = 277)   Exp. Group 1 *^b^* (*n* = 285)   Exp. Group 2 *^c^* (*n* = 261)   Exp. Group 3 *^d^* (*n* = 286)   All Groups *^e^* (*n* = 1109)                                                                                       
  --------------------- --------------------------- -------------------------------- -------------------------------- -------------------------------- ------------------------------- ----- ---- ------ ----- ----- ---- ------ ----- ----- ---- ------ ----- ----- ----- ------
  Knowledge subscale    147                         171                              24                               8.7                              154                             194   40   14.0   136   183   47   18.0   144   201   57   19.9   581   749   168   15.1
  Acceptance subscale   87                          113                              26                               9.4                              105                             141   36   12.6   95    116   21   8.0    103   138   35   12.2   390   508   118   10.6

*^a^* (*n* = 277) is the number of participants in the Control group. *^b^* (*n* = 285) is the number of participants in Experimental Group 1. *^c^* (*n* = 261) is the number of participants in Experimental Group 2. *^d^* (*n* = 286) is the number of participants in Experimental Group 3. *^e^* (*n* = 1109) is the number of participants who completed the survey through the quantitative post-test; the sum of the participants in each of the intervention groups. Diff = pre- to post-test change; Exp. = Experimental; Pre = Pre-test; Post = Post-test.

healthcare-05-00086-t003_Table 3

###### 

Intervention group scale analysis: More than half post-test responses showing HPV Knowledge and HPV vaccination acceptance.

  Scale                                                           Control *^a^* (*n* = 277)   Exp. Group 1 *^b^* (*n* = 285)   Exp. Group 2 *^c^* (*n* = 261)   Exp. Group 3 *^d^* (*n* = 286)   Across/between Groups Comparison       
  --------------------------------------------------------------- --------------------------- -------------------------------- -------------------------------- -------------------------------- ---------------------------------- --- --------------
  Knowledge Subscale                                                                                                                                                                                                                    
   Change \> half overall Responses *Agree* or *Strongly Agree*   517.89                      540.04                           585.31                           578.18                           8.443                              3   0.038 \*
   3. HPV causes genital warts                                    514.47                      506.13                           604.96                           597.37                           34.887                             3   \<0.001 \*\*
   9. I know what the HPV vaccine is for                          522.18                      548.34                           561.97                           587.06                           8.556                              3   0.036 \*
  Acceptance Subscale                                                                                                                                                                                                                   
   Change \> half Overall Responses *Agree* or *Strongly Agree*   531.84                      571.39                           550.14                           565.53                           2.628                              3   0.453

*^a^* (*n* = 277) is the number of participants in the Control group. *^b^* (*n* = 285) is the number of participants in Experimental Group 1. *^c^* (*n* = 261) is the number of participants in Experimental Group 2. *^d^* (*n* = 286) is the number of participants in Experimental Group 3. \* denotes significant 2-tailed correlation at the alpha = *p* = 0.05 level. *df =* degrees of freedom; \*\* denotes significant 2-tailed correlation at the alpha = *p* = 0.01 level; ; Exp. = Experimental.

healthcare-05-00086-t004_Table 4

###### 

Intervention group knowledge item summary: Per group respondents with more than half post-test responses showing HPV Knowledge.

  Knowledge Subscale Items                 Control *^a^* (*n* = 277)   Exp. Group 1 *^b^* (*n* = 285)   Exp. Group 2 *^c^* (*n* = 261)   Exp. Group 3 *^d^* (*n* = 286)   Overall *^e^* (*n* = 1109)                                                                                                     
  ---------------------------------------- --------------------------- -------------------------------- -------------------------------- -------------------------------- ---------------------------- ------- ----- ------- ----- ------- ----- ------- ----- ------- ----- ------- ----- ------- ----- -------
  3\. HPV causes genital warts             119                         42.96                            127                              45.85                            137                          48.07   140   49.13   117   44.83   173   66.28   124   43.36   180   62.94   497   44.82   620   55.91
  9\. I know what the HPV vaccine is for   103                         37.18                            149                              53.79                            135                          47.37   197   69.12   106   40.61   170   65.13   117   40.91   201   70.28   461   41.57   717   64.65

*^a^* (*n* = 277) is the number of participants in the Control group. *^b^* (*n* = 285) is the number of participants in Experimental Group 1. *^c^* (*n* = 261) is the number of participants in Experimental Group 2. *^d^* (*n* = 286) is the number of participants in Experimental Group 3. *^e^* (*n* = 1109) is the number of participants who completed the survey through the quantitative post-test; the sum of the participants in each of the intervention groups. Exp. = Experimental; \* denotes significant 2-tailed correlation at the alpha = *p* = 0.05 level. \*\* denotes significant 2-tailed correlation at the alpha = *p* = 0.01 level.

healthcare-05-00086-t005_Table 5

###### 

Intervention group summary: Changes in responses on the HPV knowledge and HPV vaccination acceptance subscales.

  Subscale Item                                    Paired Groups for Comparison Group: Intervention   *n*      Mean Rank   Mann-Whitney *U*   *Z*       *p* Value      Bonferroni Corrected *p* Value
  ------------------------------------------------ -------------------------------------------------- -------- ----------- ------------------ --------- -------------- --------------------------------
  Change in *Agree* and *Strongly Agree*           Control group: Control                             277      276.37                                                  
  Knowledge Responses over 50% mark                Exp. Group 1: Control and Audiovisual              285      286.48      38,052.00          −0.750    0.453          
  Control group: Control                           277                                                253.06                                                           
  Exp. Group 2: Control and Handout                261                                                286.94   31,595.50   −2.573             0.010     0.04 \*        
  Control group: Control                           277                                                266.46                                                           
  Exp. Group 3: Control, Audiovisual and Handout   286                                                297.05   35,305.50   −2.272             0.023     0.092          
  K3. HPV causes genital warts                     Control group: Control                             277      283.78                                                  
  Exp. Group 1: Control and Audiovisual            285                                                279.28   38,840.50   −0.437             0.662                    
  Control group: Control                           277                                                247.98                                                           
  Exp. Group 2: Control and Handout                261                                                292.34   30,188.50   −4.193             \<0.001   \<0.001 \*\*   
  Control group: Control                           277                                                260.70                                                           
  Exp. Group 3: Control, Audiovisual and Handout   286                                                302.63   33,711.00   −3.778             \<0.001   \<0.001 \*\*   
  K9. I know what the HPV vaccine is for           Control group: Control                             277      274.73                                                  
  Exp. Group 1: Control and Audiovisual            285                                                288.08   37,597.50   −1.181             0.238                    
  Control group: Control                           277                                                260.10                                                           
  Exp. Group 2: Control and Handout                261                                                279.47   33,546.00   −1.741             0.082                    
  Control group: Control                           277                                                265.35                                                           
  Exp. Group 3: Control, Audiovisual and Handout   286                                                298.13   34,998.50   −2.832             0.005     0.02 \*        
  Change in *Agree* and *Strongly Agree*           Control group: Control                             277      271.62                                                  
  Acceptance Responses over 50% mark               Exp. Group 1: Control and Audiovisual              285      291.11      36,734.50          −1.439    0.150          
  Control group: Control                           277                                                264.85                                                           
  Exp. Group 2: Control and Handout                261                                                274.43   34,861.00   −0.725             0.468                    
  Control group: Control                           277                                                273.38                                                           
  Exp. Group 3: Control, Audiovisual and Handout   286                                                290.35   37,222.00   −1.253             0.210                    

Exp. = Experimental; K = Knowledge subscale item; \* denotes significant 2-tailed correlation at the alpha = *p* = 0.05 level using the mathematically equivalent Bonferroni adjustment of calculated *p* value × 4. \*\* denotes significant 2-tailed correlation at the alpha = *p* = 0.01 level using the mathematically equivalent Bonferroni adjustment of calculated *p* value × 4.

healthcare-05-00086-t006_Table 6

###### 

Per question summary: Wilcoxon signed ranks test analysis of pre-test to post-test response changes.

  ---------------------------------------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------------- --------- --------------------- --------------------- ---------------------- -------------- --------- --------------------- -----------
  **Question**                                                                             **Control Group *^a^* (*n* = 277), *^A^* (*N* = 554)**   **Experimental Group 1 *^b^* (*n* = 285), *^B^* (*N* = 570)**                                                                                                                               
  **Median Pre-test**                                                                      **Median Post-test**                                     ***Z***                                                         ***p***   **Effect Size *r***   **Median Pre-test**   **Median Post-test**   ***Z***        ***p***   **Effect Size *r***   
  K1. HPV is a STD                                                                         Agree (4)                                                Agree (4)                                                       −3.944    \<0.001 \*\*          0.168 ^s^             Agree (4)              Agree (4)      −3.239    0.001 \*\*            0.136 ^s^
  K2. Condoms prevent HPV                                                                  Agree (4)                                                Agree (4)                                                       −1.563    0.118                 0.066                 Agree (4)              Neutral (3)    −0.134    0.893                 0.006
  K3. HPV causes genital warts                                                             Neutral (3)                                              Neutral (3)                                                     −0.990    0.322                 0.042                 Neutral (3)            Neutral (3)    −0.102    0.919                 0.004
  K4. People with HPV may be asymptomatic                                                  Agree (4)                                                Agree (4)                                                       −1.823    0.068                 0.077                 Agree (4)              Agree (4)      −0.876    0.381                 0.037
  K5. HPV causes sterility                                                                 Neutral (3)                                              Neutral (3)                                                     −3.030    0.002 \*\*            0.129 ^s^             Neutral (3)            Neutral (3)    −1.471    0.141                 0.062
  A1. Worry that I/my child(ren)can get HPV                                                Neutral (3)                                              Neutral (3)                                                     −3.879    \<0.001 \*\*          0.165 ^s^             Neutral (3)            Neutral (3)    −4.078    \<0.001 \*\*          0.171 ^s^
  K6. HPV causes cervical cancer                                                           Agree (4)                                                Agree (4)                                                       −3.724    \<0.001 \*\*          0.158 ^s^             Agree (4)              Agree (4)      −4.336    \<0.001 \*\*          0.182 ^s^
  K7. Treatment of HPV is painful                                                          Neutral (3)                                              Neutral (3)                                                     −1.576    0.115                 0.067                 Neutral (3)            Neutral (3)    −0.858    0.391                 0.036
  K8. Required vaccines protect from getting disease from unvaccinated persons             Agree (4)                                                Agree (4)                                                       −1.324    0.186                 0.056                 Agree (4)              Agree (4)      −3.292    0.001 \*\*            0.138 ^s^
  K9. I know what the HPV vaccine is for                                                   Neutral (3)                                              Agree (4)                                                       −6.689    \<0.001 \*            0.284 ^m^             Neutral (3)            Agree (4)      −6.924    \<0.001 \*\*          0.029 ^s^
  K10. Genital warts make it hard to have a sexual partner                                 Agree (4)                                                Agree (4)                                                       −0.845    0.398                 0.036                 Agree (4)              Agree (4)      −1.289    0.197                 0.054
  K11. Children should only be vaccinated for serious diseases                             Neutral (3)                                              Neutral (3)                                                     −0.524    0.600                 0.022                 Neutral (3)            Neutral (3)    −0.320    0.749                 0.013
  A2. Vaccines that have been used awhile are more trustworthy                             Agree (2)                                                Agree (2)                                                       −1.547    0.122                 0.066                 Agree (2)              Agree (2)      −1.068    0.285                 0.045
  A3. Research improves vaccines                                                           Agree (4)                                                Agree (4)                                                       −1.122    0.262                 0.048                 Agree (4)              Agree (4)      −2.763    0.006 \*\*            0.116 ^s^
  A4. Healthy children do not need vaccines                                                Disagree (4)                                             Disagree (4)                                                    −1.506    0.132                 0.064                 Disagree (4)           Disagree (4)   −1.898    0.058                 0.079
  A5. HPV vaccination would prevent problems for myself/my child(ren)                      Neutral (3)                                              Agree (4)                                                       −3.088    0.002 \*\*            0.131 ^s^             Agree (4)              Agree (4)      −3.130    0.002 \*\*            0.131 ^s^
  A6. Giving a new vaccine is like performing an experiment                                Neutral (3)                                              Neutral (3)                                                     −0.176    0.860                 0.007                 Neutral (3)            Neutral (3)    −0.071    0.943                 0.003
  A7. HPV vaccination before teenage is a good idea                                        Neutral (3)                                              Neutral (3)                                                     −4.118    \<0.001 \*\*          0.175 ^s^             Neutral (3)            Neutral (3)    −3.162    0.002 \*\*            0.132 ^s^
  A8. Teenagers should be able to get HPV vaccination without parental consent             Neutral (3)                                              Neutral (3)                                                     −1.243    0.214                 0.053                 Neutral (3)            Neutral (3)    −0.958    0.338                 0.040
  A9. If the HPV vaccine were available, I/my child(ren) would be vaccinated against HPV   Neutral (3)                                              Neutral (3)                                                     −1.250    0.211                 0.053                 Neutral (3)            Neutral (3)    −2.748    0.006 \*\*            0.115 ^s^
  A10. Vaccines are painful, so I would not vaccinate myself/my child(ren)                 Neutral (3)                                              Disagree (4)                                                    −0.707    0.480                 0.030                 Disagree (4)           Disagree (4)   −1.110    0.267                 0.046
  A11. Will only vaccinate myself/my child(ren) against HPV if required                    Neutral (3)                                              Neutral (3)                                                     −1.968    0.049 \*              0.084 ^s^             Neutral (3)            Neutral (3)    −1.174    0.240                 0.049
  A12. Despite cost I will vaccinate myself/my child(ren)                                  Neutral (3)                                              Neutral (3)                                                     −2.332    0.020 \*              0.099 ^s^             Neutral (3)            Neutral (3)    −3.623    \<0.001 \*\*          0.152 ^s^
  A13. If my doctor recommends I will vaccinate myself/my child(ren)                       Agree (4)                                                Agree (4)                                                       −0.555    0.579                 0.024                 Agree (4)              Agree (4)      −2.035    0.042 \*              0.085 ^s^
  A14. When I decide to vaccinate myself/my child(ren) it will be done                     Agree (4)                                                Agree (4)                                                       −0.091    0.927                 0.004                 Agree (4)              Agree (4)      −1.236    0.217                 0.052
  **Question**                                                                             **Control Group *^c^* (*n* = 261), *^C^* (*N* = 522)**   **Experimental Group 1 *^d^* (*n* = 286), *^D^* (*N* = 572)**                                                                                                                               
  **Median Pre-test**                                                                      **Median Post-test**                                     ***Z***                                                         ***p***   **Effect Size *r***   **Median Pre-test**   **Median Post-test**   ***Z***        ***p***   **Effect Size *r***   
  K1. HPV is a STD                                                                         Agree (4)                                                Agree (4)                                                       −5.952    \<0.001 \*\*          0.260^m^              Agree (4)              Agree (4)      −5.569    \<0.001 \*\*          0.233 ^m^
  K2. Condoms prevent HPV                                                                  Agree (4)                                                Agree (4)                                                       −1.498    0.134                 0.066                 Neutral (3)            Neutral (3)    −0.007    0.995                 0.000 ^e^
  K3. HPV causes genital warts                                                             Neutral (3)                                              Agree (4)                                                       −5.932    \<0.001 \*\*          0.260 ^m^             Neutral (3)            Agree (4)      −4.880    \<0.001 \*\*          0.204 ^m^
  K4. People with HPV may be asymptomatic                                                  Agree (4)                                                Agree (4)                                                       −2.329    0.020 \*              0.102 ^s^             Agree (4)              Agree (4)      −4.131    \<0.001 \*\*          0.173 ^s^
  K5. HPV causes sterility                                                                 Neutral (3)                                              Neutral (3)                                                     −0.754    0.451                 0.033                 Neutral (3)            Neutral (3)    −1.619    0.105                 0.068
  A1. Worry that I/my child(ren) can get HPV                                               Neutral (3)                                              Neutral (3)                                                     −3.471    0.001 \*\*            0.152 ^s^             Neutral (3)            Neutral (3)    −5.296    \<0.001 \*\*          0.221 ^m^
  K6. HPV causes cervical cancer                                                           Agree (4)                                                Agree (4)                                                       −4.662    \<0.001 \*\*          0.204 ^m^             Agree (4)              Agree (4)      −7.387    \<0.001 \*\*          0.309 ^m^
  K7. Treatment of HPV is painful                                                          Neutral (3)                                              Neutral (3)                                                     −1.245    0.213                 0.054                 Neutral (3)            Neutral (3)    −1.326    0.185                 0.055
  K8. Required vaccines protect from getting disease from unvaccinated persons             Agree (4)                                                Agree (4)                                                       −2.836    0.005 \*\*            0.124 ^s^             Agree (4)              Agree (4)      −2.166    0.030 \*              0.091
  K9. I know what the HPV vaccine is for                                                   Neutral (3)                                              Agree (4)                                                       −7.145    \<0.001 \*\*          0.313 ^m^             Neutral (3)            Agree (4)      −8.532    \<0.001 \*\*          0.357 ^m^
  K10. Genital warts make it hard to have a sexual partner                                 Agree (4)                                                Agree (4)                                                       −2.784    0.005 \*\*            0.122 ^s^             Agree (4)              Agree (4)      −1.724    0.085                 0.072
  K11. Children should only be vaccinated for serious diseases                             Neutral (3)                                              Neutral (3)                                                     −0.182    0.855                 0.008                 Neutral (3)            Neutral (3)    −1.473    0.141                 0.062
  A2. Vaccines that have been used awhile are more trustworthy                             Agree (2)                                                Agree (2)                                                       −0.708    0.479                 0.031                 Disagree (4)           Disagree (4)   −1.266    0.206                 0.053
  A3. Research improves vaccines                                                           Agree (4)                                                Agree (4)                                                       −1.006    0.315                 0.044                 Agree (4)              Agree (4)      −3.447    0.001 \*\*            0.144 ^s^
  A4. Healthy children do not need vaccines                                                Disagree (4)                                             Disagree (4)                                                    −1.321    0.187                 0.058                 Disagree (4)           Disagree (4)   −0.638    0.523                 0.027
  A5. HPV vaccination would prevent problems for myself/my child(ren)                      Agree (4)                                                Agree (4)                                                       −3.530    \<0.001 \*\*          0.154 ^s^             Neutral (3)            Agree (4)      −5.684    \<0.001 \*\*          0.238 ^m^
  A6. Giving a new vaccine is like performing an experiment                                Neutral (3)                                              Neutral (3)                                                     −0.645    0.519                 0.028                 Neutral (3)            Neutral (3)    −0.858    0.391                 0.036
  A7. HPV vaccination before Teenage is a good idea                                        Neutral (3)                                              Neutral (3)                                                     −3.491    \<0.001 \*\*          0.153 ^s^             Neutral (3)            Neutral (3)    −3.182    0.001 \*\*            0.133 ^s^
  A8. Teenagers should be able to Get HPV vaccination without parental consent             Neutral (3)                                              Neutral (3)                                                     −1.867    0.062                 0.082                 Neutral (3)            Neutral (3)    −2.277    0.023 \*              0.095 ^s^
  A9. If the HPV vaccine were available, I/my child(ren) would be vaccinated against HPV   Neutral (3)                                              Neutral (3)                                                     −0.593    0.553                 0.026                 Neutral (3)            Neutral (3)    −1.929    0.054                 0.081
  A10. Vaccines are painful, so I Would not vaccinate myself/my child(ren)                 Disagree (4)                                             Disagree (4)                                                    −1.653    0.098                 0.072                 Agree (2)              Disagree (4)   −0.376    0.707                 0.016
  A11. Will only vaccinate myself/my child(ren) against HPV if required                    Neutral (3)                                              Neutral (3)                                                     −0.185    0.854                 0.008                 Neutral (3)            Neutral (3)    −3.096    0.002 \*\*            0.130 ^s^
  A12. Despite cost I will vaccinate myself/my child(ren)                                  Neutral (3)                                              Neutral (3)                                                     −2.761    0.006 \*\*            0.121 ^s^             Neutral (3)            Agree (4)      −4.747    \<0.001 \*\*          0.200 ^s^
  A13. If my doctor recommends I will vaccinate myself/my child(ren)                       Agree (4)                                                Agree (4)                                                       −2.237    0.025 \*              0.098 ^s^             Agree (4)              Agree (4)      −2.833    0.005 \*\*            0.118 ^s^
  A14. When I decide to vaccinate myself/my child(ren) it will be done                     Agree (4)                                                Agree (4)                                                       −2.928    0.003 \*\*            0.128 ^s^             Agree (4)              Agree (4)      −0.698    0.485                 0.030
  ---------------------------------------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------------- --------- --------------------- --------------------- ---------------------- -------------- --------- --------------------- -----------

*^a^* (*n* = 277) is the number of participants in the Control group. *^A^* (*N* = 554) is twice the number of participants in the Control group, accounting for the number of pre- and post-tests. *^b^* (*n* = 285) is the number of participants in Experimental Group 1. *^B^* (*N* = 554) is twice the number of participants in Experimental Group 1, accounting for the number of pre- and post-tests. *^c^* (*n* = 261) is the number of participants in Experimental Group 2. *^C^* (*N* = 554) is twice the number of participants in Experimental Group 2, accounting for the number of pre- and post-tests. *^d^* (*n* = 286) is the number of participants in Experimental Group 3. *^D^* (*N* = 554) is twice the number of participants in Experimental Group 3, accounting for the number of pre- and post-tests. A = Acceptance subscale item; K = Knowledge subscale item; e = actual r value is .0003; m = medium effect size; s = small effect size. \* denotes significant 2-tailed correlation at the alpha = *p* = 0.05 level. \*\* denotes significant 2-tailed correlation at the alpha = *p* = 0.01 level.
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###### 

Covariates affect HPV knowledge and HPV vaccination acceptance pre-test to post-test change.

  Covariate                                                        Knowledge Subscale Change   Acceptance Subscale Change            
  ---------------------------------------------------------------- --------------------------- ---------------------------- -------- ------------
  Young Adults' Actual Age in Years                                −0.011                      0.796                        0.073    0.088
  Parents' Actual Age in Years                                     0.093                       0.027 \*                     0.119    0.005 \*\*
  Number of Female Children                                        0.017                       0.690                        0.008    0.846
  Number of Male Children                                          0.093                       0.028 \*                     0.017    0.693
  Number of HPV Vaccine Doses Child(ren) or Young Adult Received   0.092                       0.176                        −0.171   0.011 \*
  Household Size                                                   0.008                       0.799                        0.041    0.171
  Number of Children in the Household                              0.016                       0.602                        0.52     0.084
  Generations Born in the US                                       0.067                       0.032 \*                     0.067    0.032 \*
  Non-US Born: Years Lived in the US                               −0.085                      0.425                        0.102    0.337
  Religious Services Frequency                                     0.025                       0.403                        0.026    0.385
  Education Level                                                  −0.013                      0.661                        0.023    0.443
  High School non-completer's Grade                                0.042                       0.815                        0.156    0.379
  Income Level                                                     −0.024                      0.424                        0.021    0.491

Unadjusted data. \* denotes significant 2-tailed correlation at the alpha = *p* = 0.05 level. \*\* denotes significant 2-tailed correlation at the alpha = *p* = 0.01 level.
